Abstract
Depression is a risk factor for Alzheimer’s disease (AD), but evidence for their genetic relationship is mixed. Assessing depression symptom specific genetic associations may better clarify this relationship.
Using data from the UK Biobank, the GLAD Study and PROTECT, we performed the largest genome-wide meta-analyses (GWAS) of the nine depression symptom items, plus their sum score, on the Patient Health Questionnaire (PHQ-9) (GWAS equivalent N: 224,535—308,421). We assessed global/local genetic correlations and statistical colocalisation between depression phenotypes and AD across six AD GWAS with varying proportions of clinical and proxy (family history) case ascertainment. We assessed bi-directional causal associations using Mendelian randomisation (MR) and the predictiveness of depression phenotype polygenic risk scores (PRS) for AD case/control status in three clinical AD cohorts.
Our GWAS meta-analyses identified 37 genomic risk loci across the ten depression symptom phenotypes. Of the 72 global genetic correlation tests conducted between depression/depression symptoms and AD, 20 were significant at pFDR≤ 0.05. Only one significant genetic correlation was identified with AD GWAS containing clinical-only cases. Colocalisation was not identified at loci contains local genetic correlation but was identified in the region of transmembrane protein 106B (TMEM106B) between multiple depression phenotypes and both clinical-only and clinical+proxy AD. MR and PRS analyses did not yield statistically significant results.
Our findings do not demonstrate a causal role of depression/depression symptoms on AD and suggest that previous evidence of their genetic overlap may be driven by the inclusion of proxy cases/controls. However, the identification of colocalisation at TMEM106B warrants further investigation.
Competing Interest Statement
CML is on the Scientific Advisory Board of Myriad Neuroscience and has received honoraria for consultancy from UCB.
Funding Statement
See funding and acknowledgement statement in the main body of the manuscript
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee/IRB of King's College London gave ethical approval for this work Ethical approval for the UK Biobank study has been granted by the National Information Governance Board for Health and Social Care and the NHS North West Multicentre Research Ethics Committee (11/NW/0382). Data access permission has been granted under UK Biobank application 18177. Written informed consent was obtained from all participants by the UK Biobank. The GLAD Study was approved by the London - Fulham Research Ethics Committee on 21st August 2018 (REC reference: 18/LO/1218) following a full review by the committee. The NIHR BioResource has been approved as a Research Tissue Bank by the East of England - Cambridge Central Committee (REC reference: 17/EE/0025). The PROTECT study received ethical approval from the UK London Bridge National Research Ethics Committee (Ref: 13/LO/1578) Data were obtained from ADNI, AddNeuroMed and GERAD1 following formal request to each consortia. Permission was granted for the use of data.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Author added; author affiliations updated; supplementary figures added
Data Availability
All GWAS summary statistics generated in the process of conducting this study will be deposited in the NHGRI-EBI Catalog of human genome-wide association studies (GWAS Catalog) following peer-review and publication. This study was pre-registered on the Open Science Framework (https://osf.io/94q35/?view_only=e77f72d4100d47eea7f3ef07dfa9c059).